Search filters

List of works by Monica Crugnola

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

scientific article published on 17 November 2020

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line

scientific article

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

scientific article

BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS

scientific article published on 01 December 2020

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

scientific article published on 27 June 2017

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

Dasatinib first-line: Multicentric Italian experience outside clinical trials

scientific article

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar

scientific article published on 05 June 2018

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

scholarly article by Francesca Palandri et al published November 2018 in Leukemia Research

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study

scientific article

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients

scientific article published on 6 April 2018

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

scientific article published on September 2016

Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

scientific article published on 02 September 2019

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

scientific article published on 27 August 2016

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

scientific article published in August 2013

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

scientific article published on 07 June 2019

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

scientific article published on 04 December 2018

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

scientific article published on 19 July 2012

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

scientific article published on 20 December 2019

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

scientific article published on 9 March 2016

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

scientific article published on 28 February 2019

Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline

scientific article published on 07 August 2019

Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice

scientific article published on 19 April 2018

RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA

scientific article published on 09 April 2020

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

scientific article published on 30 May 2018

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

scientific article published on 07 January 2021

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients

scientific article published on 16 July 2018

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

scientific article published on 21 November 2020

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

scientific article

Paulina is supported by:

About Paulina

Help